$45.53
2.00% yesterday
Nasdaq, Nov 25, 10:01 pm CET
ISIN
US74366E1029
Symbol
PTGX

Protagonist Therapeutics, Inc. Stock price

$45.53
-1.73 3.66% 1M
+15.12 49.72% 6M
+22.60 98.56% YTD
+28.11 161.37% 1Y
+10.82 31.17% 3Y
+37.19 445.92% 5Y
+33.83 289.15% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
-0.93 2.00%
ISIN
US74366E1029
Symbol
PTGX
Sector
Industry

Key metrics

Market capitalization $2.71b
Enterprise Value $2.26b
P/E (TTM) P/E ratio 17.08
EV/FCF (TTM) EV/FCF 9.84
EV/Sales (TTM) EV/Sales 6.97
P/S ratio (TTM) P/S ratio 8.38
P/B ratio (TTM) P/B ratio 5.09
Revenue (TTM) Revenue $323.80m
EBIT (operating result TTM) EBIT $149.11m
Free Cash Flow (TTM) Free Cash Flow $229.23m
Cash position $468.72m
EPS (TTM) EPS $2.67
P/E forward 16.79
P/S forward 8.35
EV/Sales forward 6.94
Short interest 5.58%
Show more

Is Protagonist Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Protagonist Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Protagonist Therapeutics, Inc. forecast:

8x Buy
100%

Analyst Opinions

8 Analysts have issued a Protagonist Therapeutics, Inc. forecast:

Buy
100%

Financial data from Protagonist Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
324 324
-
100%
- Direct Costs 3.19 3.19
16% 16%
1%
321 321
11,801% 11,801%
99%
- Selling and Administrative Expenses 36 36
36% 36%
11%
- Research and Development Expense 132 132
9% 9%
41%
152 152
201% 201%
47%
- Depreciation and Amortization 3.19 3.19
16% 16%
1%
EBIT (Operating Income) EBIT 149 149
197% 197%
46%
Net Profit 171 171
222% 222%
53%

In millions USD.

Don't miss a Thing! We will send you all news about Protagonist Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Protagonist Therapeutics, Inc. Stock News

Neutral
Accesswire
4 days ago
NEWARK, CA / ACCESSWIRE / November 22, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D.
Neutral
Accesswire
7 days ago
Webcast and conference call to be held be on Thursday, November 21st at 4:30 pm ET, dial in information below NEWARK, CA / ACCESSWIRE / November 19, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that the company will host a conference call and webcast to announce its oral peptide IL-17 antagonist development candidate and to share in vitro and pre-clinic...
Neutral
Accesswire
19 days ago
Top line results for JNJ-2113 Phase 3 ICONIC-LEAD and Phase 3 ICONIC-TOTAL clinical trials in patients with moderate to severe psoriasis expected in Q4 2024 Top line results for JNJ-2113 Phase 2b ANTHEM clinical trial in moderate to severe ulcerative colitis expected in Q1 2025 Top line results for rusfertide Phase 3 VERIFY clinical trial in polycythemia vera expected in Q1 2025 Development can...
More Protagonist Therapeutics, Inc. News

Company Profile

Protagonist Therapeutics, Inc. engages in the research and development of novel constrained peptide-based drug candidates that address significant unmet medical needs. Its product pipeline include PTG-300, PTG-200, and PN-943 The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.

Head office United States
CEO Dinesh Patel
Employees 112
Founded 2006
Website www.protagonist-inc.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today